MTNB - Matinas BioPharma Holdings, Inc.
| Previous Close | 1.0300 |
| Open | 1.0100 |
| Bid | 0.0000 x 800 |
| Ask | 0.0000 x 800 |
| Day's Range | 0.9700 - 1.0300 |
| 52 Week Range | 0.3240 - 1.5000 |
| Volume | 620,586 |
| Avg. Volume | 1,041,964 |
| Market Cap | 147.226M |
| Beta (3Y Monthly) | 3.65 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.1530 |
| Earnings Date | Aug 6, 2018 - Aug 10, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.50 |
- Thomson Reuters StreetEvents•12 days ago
Edited Transcript of MTNB earnings conference call or presentation 2-Apr-19 12:00pm GMT
Full Year 2018 Matinas BioPharma Holdings Inc Earnings Call
- GlobeNewswire•21 days ago
Matinas BioPharma Reports 2018 Financial Results and Provides Corporate Update
– Key focus on advancing the development of MAT9001, a potential best-in-class cardiovascular therapy in what is projected to be a new, multi-billion dollar prescription-only.
- GlobeNewswire•28 days ago
Matinas BioPharma to Announce Full-Year 2018 Operational and Financial Results on April 2, 2019
The call will be led by Jerome D. Jabbour, Chief Executive Officer of Matinas. Forward Looking Statements: This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including those relating to the Company's anticipated capital and liquidity needs, strategic focus and the future development of its product candidates, including MAT9001 and MAT2203, the anticipated timing of regulatory submissions, the anticipated timing of clinical studies, the anticipated timing of regulatory interactions, the Company’s ability to identify and pursue development and partnership opportunities for its products or platform delivery technology on favorable terms, if at all, and the ability to obtain required regulatory approval and other statements that are predictive in nature, that depend upon or refer to future events or conditions.
- Business Wire•last month
Matinas BioPharma to Present at the 31st Annual ROTH Conference
Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced that Jerome D. Jabbour, Chief Executive Officer, will present at the 31st Annual ROTH Conference on Tuesday, March 19 at 2:30 PM PT in Dana Point, CA. As part of his presentation, Mr. Jabbour will provide a corporate update and will discuss MAT9001, the Company’s proprietary prescription-only omega-3 fatty acid-based composition. Matinas is developing MAT9001 for therapeutic applications in the cardiovascular and metabolic fields with the support of a world-class team of clinical key opinion leaders and regulatory consultants.
- Business Wire•last month
Matinas BioPharma Announces Pricing of Public Offering of Common Stock
Matinas BioPharma Holdings, Inc. (“Matinas BioPharma” or the “Company”) -- (NYSE AMER:MTNB), a clinical-stage biopharmaceutical company, today announced the pricing of its underwritten registered public offering of 27,272,727 shares of its common stock, offered at a price to the public of $1.10 per share for expected gross proceeds of $30.0 million, before deducting underwriting discounts and commissions and other estimated offering expenses. In addition, Matinas BioPharma has granted the underwriters a 30-day option to purchase up to an additional 4,090,909 shares of its common stock on the same terms and conditions. All of the shares in the offering are being sold by Matinas BioPharma.
- Business Wire•last month
Matinas BioPharma Announces Proposed Public Offering of Common Stock
Matinas BioPharma Holdings, Inc. (“Matinas BioPharma” or the “Company”) -- (NYSE AMER:MTNB), a clinical-stage biopharmaceutical company, today announced that it has commenced an underwritten public offering of its common stock. All of the shares to be sold in the offering are to be sold by Matinas BioPharma. In connection with the offering, Matinas BioPharma intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering.
- GlobeNewswire•2 months ago
Prominent Cardiovascular Expert, James J. Ferguson, M.D., FACC, FAHA Joins Matinas BioPharma as Chief Medical Officer
Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced that it has appointed a prominent cardiovascular medical and clinical development expert, James (“Terry”) J. Ferguson, M.D., FACC, FAHA, as its Chief Medical Officer.
- ACCESSWIRE•3 months ago
Biotech Breaking Out
HENDERSON, NV / ACCESSWIRE / January 16, 2019 / Since hitting its lows on Dec. 26, biotech has soared more than 20 percent as of Friday, and was posting its best start to a year since 2012. Here are a ...
- GlobeNewswire•3 months ago
Matinas BioPharma Announces a Research Evaluation with Top Global Pharma Company Based on Its Proprietary Drug Delivery Platform
Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical stage biopharmaceutical company, today announced they have signed an agreement with an undisclosed top global pharmaceutical company aimed to evaluate synergistic effects of Matinas’ lipid-nano-crystal (“LNC”) platform delivery technology with their partner’s nucleic acid polymer technology. Formulations will be developed using Matinas’ LNC delivery technology which enables the development of a wide range of difficult-to-deliver molecules. For competitive reasons, the agreement stipulates certain confidential provisions, including the pharmaceutical company’s identity, the therapeutic molecule(s), the intended targets and the financial terms of the agreement.
- GlobeNewswire•4 months ago
Matinas BioPharma Appoints Keith A. Kucinski, CPA, MBA as Chief Financial Officer
Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced that it has appointed Keith A. Kucinski, CPA, MBA as Chief Financial Officer. Mr. Kucinski brings to Matinas over 20 years of diversified and broad finance expertise with demonstrated leadership and success in financial and strategic planning, accessing the capital markets and mergers and acquisitions across the healthcare and business consulting industries. Jerome D. Jabbour, Chief Executive Officer, commented, “As we look to drive our Company forward in 2019 and maximize the value of our products and platform technology, we have taken deliberate steps to bolster our management team over the past few months.
- GlobeNewswire•4 months ago
Matinas BioPharma to Present at Biotech Showcase 2019
As part of his presentation, Mr. Jabbour will provide a corporate update and will discuss MAT9001, the Company’s proprietary prescription-only omega-3 fatty acid-based composition, comprised of eicosapentaenoic acid (EPA), docosapentaenoic acid (DPA), a highly potent but less prevalent omega-3 fatty acid with very unique properties, and other omega-3 fatty acids. The Company recently announced the formation of a Scientific Advisory Board to guide clinical development strategy of its potential best-in-class prescription-only omega-3, MAT9001, and appointed three internationally renowned experts as its first members. Matinas is developing MAT9001 for therapeutic applications in the cardiovascular and metabolic fields with the support of a world-class team of clinical key opinion leaders and regulatory consultants.
- GlobeNewswire•4 months ago
Matinas BioPharma Appoints Harold E. Bays, M.D. to its Cardiovascular Health Scientific Advisory Board
Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical stage biopharmaceutical company, today announced the appointment of Harold E. Bays, M.D. to its Scientific Advisory Board (SAB). Dr. Bays is Board Certified in Endocrinology and Internal Medicine, Diplomate of the American Board of Clinical Lipidology, and Diplomate of the American Board of Obesity Medicine. Dr. Bays joins the Company’s recently appointed SAB members, Christie M. Ballantyne, M.D., John J.P. Kastelein, M.D., Ph.D., FESC, and Kevin C. Maki, Ph.D., now representing four of the world’s leading lipid specialists and cardiovascular health experts.
- GlobeNewswire•5 months ago
Matinas BioPharma Assembles World Class Scientific Advisory Board to Guide Clinical Development Strategy of Potential Best-in-Class Prescription-Only Omega-3, MAT9001
BEDMINSTER, N.J., Dec. 06, 2018 -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical stage biopharmaceutical company, today announced that it has established a.
- GlobeNewswire•5 months ago
Detailed Research: Economic Perspectives on Sunstone Hotel Investors, Acadia Realty Trust, Matinas Biopharma, Compass Diversified, Aspen Insurance, and Superior Drilling Products — What Drives Growth in Today's Competitive Landscape
NEW YORK, Nov. 26, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- Simply Wall St.•5 months ago
How Does Investing In Matinas BioPharma Holdings Inc (NYSEMKT:MTNB) Impact The Volatility Of Your Portfolio?
If you own shares in Matinas BioPharma Holdings Inc (NYSEMKT:MTNB) then it’s worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a Read More...
- ACCESSWIRE•5 months ago
4 Stocks To Watch As Healthcare Technology Industry Is Expecting Rapid Growth Through 2025
CORAL GABLES, FL / ACCESSWIRE / November 13, 2018 / The U.S. patient engagement solutions market size is anticipated to reach $12.3 billion by 2025, expanding at a CAGR of 19.5% over the forecast period according to reports from Research And Markets*. With the volatility in today's market, many investors have turned to biotechnology and healthcare stocks as a safe haven from the broader market activity. Furthermore, the new age of technology and aging population unable to frequently visit a physical doctor's office has created a larger demand for technology intervention within the healthcare industry.
- ACCESSWIRE•5 months ago
3 Healthcare Stocks Pushing The Boundaries Of Innovation: Premier Health Group, Inc. (OTC: PHGRF) (CSE: PHGI), Matinas BioPharma Holdings, Inovalon Holdings
The Smart Medical Devices Market, for example, is expected to witness healthy growth (no pun intended) according to a report by Market Research Future*. Biotech companies have found that this demand is unwavering and are working toward catering to it by increasing investments toward the development of more efficient methods of self-administration of drugs and diagnosis. Sector trends in healthcare technology and new treatments for rare diseases have sparked more interest in sector stocks.
- GlobeNewswire•5 months ago
Matinas BioPharma Reports Third Quarter 2018 Financial Results and Provides Corporate Update
– Key focus on advancing the development of MAT9001, a proprietary, potential best-in-class cardiovascular therapy in what is projected to be a new, multi-billion dollar.
